[O4] Oral Presentations 4

5:24 PM - 5:31 PM JST(8:24 AM - 8:31 AM UTC)

[O4-08] A phase 1 clinical trial of a new oncolytic herpes virus expressing anti-VEGF antibody in patients with malignant glioma

*Tomoki Todo¹, Hirotaka Ito¹, Minoru Tanaka¹ (1. Institute of Medical Science, The University of Tokyo (Japan))

Keywords:

herpes simplex virus type 1,oncolytic virus therapy,malignant glioma,clinical trial,anti-VEGF antibody,bevacizumab

Password required to view

Log in

or